StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a research note published on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.
Evogene Trading Up 0.9 %
Shares of NASDAQ EVGN opened at $0.60 on Friday. Evogene has a 12-month low of $0.45 and a 12-month high of $1.20. The business’s fifty day simple moving average is $0.67 and its 200-day simple moving average is $0.75.
Evogene (NASDAQ:EVGN – Get Free Report) last posted its earnings results on Thursday, May 23rd. The biotechnology company reported ($0.08) EPS for the quarter. The business had revenue of $4.19 million during the quarter. Evogene had a negative net margin of 233.66% and a negative return on equity of 70.96%.
Hedge Funds Weigh In On Evogene
An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets lifted its holdings in shares of Evogene Ltd. (NASDAQ:EVGN – Free Report) by 30.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 91,400 shares of the biotechnology company’s stock after buying an additional 21,500 shares during the period. BNP Paribas Financial Markets owned approximately 0.22% of Evogene worth $69,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.40% of the company’s stock.
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Featured Stories
- Five stocks we like better than Evogene
- Stock Average Calculator
- Major EV Stock Prepares for Q2 Earnings: What You Need to Know
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Why This AI Stock is Rising Despite Tech Sell-Off
- Short Selling: How to Short a Stock
- Investors Are Moving into Bonds and Small Cap Stocks: Here’s Why
Receive News & Ratings for Evogene Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Evogene and related companies with MarketBeat.com’s FREE daily email newsletter.
